bioRxiv · 10.1101/2020.08.14.251538
Differential methylation as a mediator of COVID-19 susceptibility
Abstract
The COVID-19 outbreak shows a huge variation in prevalence and mortality on geographical level but also within populations1. The ACE2 gene, identified as the SARS-CoV2 receptor, has been shown to facilitate the viral invasion and people with higher ACE2 expression generally are more severely affected2, 3. As there is a lot of variability in ACE2 expression between individuals we hypothesized that differential DNA methylation profiles could be (one of) the confounding factors explaining this variability. Here we show that epigenetic profiling of host tissue, especially in the ACE2 promoter region and its homologue ACE1, may be important risk factors for COVID-19. Our results propose that variable methylation can explain (part of) the differential susceptibility, symptom severity and death rate for COVID-19. Our findings are a promising starting point to further evaluate the potential of ACE1/2 methylation and other candidates as a predictor for clinical outcome upon SARS-CoV2 infection.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Steyaert, S., Trooskens, G., Delanghe, J. R., Van Criekinge, W.. 2020-08-14. Differential methylation as a mediator of COVID-19 susceptibility. https://doi.org/10.1101/2020.08.14.251538
Cite the original work for its findings. Save a collection to share your selection of sources.